Biotech News

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

Humacyte (HUMA)Humacyte2026-10-12 12:00 ESTClinical readout

- Interim Phase 3 findings will be presented in a prestigious late-breaking oral session at the leading meeting for kidney health professionals. – Randomized trial compares the acellular tissue engineered vessel (ATEV) with autogenous arteriovenous fistula in female patients with end-stage kidney

Humacyte

Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...

Recent company news

HUMAHumacyte2026-10-15 12:00 EST

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

HUMAHumacyte2026-10-12 12:00 EST